KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Change in Account Payables (2016 - 2025)

Globus Medical (GMED) has disclosed Change in Account Payables for 15 consecutive years, with $9.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 44.16% year-over-year to $9.1 million, compared with a TTM value of $8.5 million through Dec 2025, down 51.95%, and an annual FY2025 reading of $8.5 million, down 51.95% over the prior year.
  • Change in Account Payables was $9.1 million for Q4 2025 at Globus Medical, up from $3.4 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $17.3 million in Q2 2024 and bottomed at -$10.3 million in Q3 2024.
  • Average Change in Account Payables over 5 years is $1.5 million, with a median of $473500.0 recorded in 2021.
  • The sharpest move saw Change in Account Payables skyrocketed 1588.34% in 2021, then plummeted 811.11% in 2022.
  • Year by year, Change in Account Payables stood at $1.2 million in 2021, then soared by 244.88% to $4.0 million in 2022, then crashed by 256.35% to -$6.3 million in 2023, then soared by 361.03% to $16.4 million in 2024, then plummeted by 44.16% to $9.1 million in 2025.
  • Business Quant data shows Change in Account Payables for GMED at $9.1 million in Q4 2025, $3.4 million in Q3 2025, and -$3.2 million in Q2 2025.